Cargando…

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

SIMPLE SUMMARY: Combining EGFR-targeted therapies, such as cetuximab, with a potent inhibitor of the PI3K/Akt pathway may be a novel therapeutic strategy that could potentially overcome/circumvent resistance. Interestingly, all pathways downstream of EGFR play a role in the regulation of the autopha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaryouh, Hannah, Van Loenhout, Jinthe, Peeters, Marc, Vermorken, Jan Baptist, Lardon, Filip, Wouters, An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776372/ https://www.ncbi.nlm.nih.gov/pubmed/36551613 http://dx.doi.org/10.3390/cancers14246128

Ejemplares similares

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
por: Zaryouh, Hannah, et al.
Publicado: (2021)

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
por: Baysal, Hasan, et al.
Publicado: (2021)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
por: Boeckx, Carolien, et al.
Publicado: (2014)

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
por: Boeckx, Carolien, et al.
Publicado: (2015)

In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells
por: Wouters, An, et al.
Publicado: (2010)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects
por: Van Loenhout, Jinthe, et al.
Publicado: (2020)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer
por: Ye, Mingtong, et al.
Publicado: (2017)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
por: Van Loenhout, Jinthe, et al.
Publicado: (2021)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
por: Kwon, Yoojung, et al.
Publicado: (2019)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
por: Bernard, Monique, et al.
Publicado: (2020)

Head and Neck Cancer
por: Psyrri, Amanda, et al.
Publicado: (2009)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
por: Szturz, Petr, et al.
Publicado: (2016)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
por: de Kort, W. W. B., et al.
Publicado: (2021)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
por: Freire Boullosa, Laurie, et al.
Publicado: (2022)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

EGFR Mutations in Head and Neck Squamous Cell Carcinoma
por: Nair, Sindhu, et al.
Publicado: (2022)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines
por: Baba, Yuh, et al.
Publicado: (2015)

Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

Cellular senescence in cancer: clinical detection and prognostic implications
por: Domen, Andreas, et al.
Publicado: (2022)

Study of EGFR mutations in head and neck squamous cell carcinomas
por: Kaur, Gurpreet, et al.
Publicado: (2021)

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
por: Schuler, Patrick J, et al.
Publicado: (2011)

Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
por: Limame, Ridha, et al.
Publicado: (2012)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Hsu, Chia-Chi, et al.
Publicado: (2021)

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
por: Baba, Yuh, et al.
Publicado: (2012)

Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
por: Bossi, Paolo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4sbbar27kpdr4pi8rdf4ve3ljt